P35968 VGFR2_HUMAN
Gene name: KDR
Protein name: Vascular endothelial growth factor receptor 2
List of molecules and drugs that target protein P35968
# | DrugDomain Data | DrugBank Accession | Name | Drug action | Affinity data | InChI Key | SMILES |
---|---|---|---|---|---|---|---|
1 | P35968_DB00398 | DB00398 | Sorafenib | antagonist | Ki(nM) = 0.021 IC50(nM) = 0.06 Kd(nM) = 33.0 EC50(nM) = 500.0 | MLDQJTXFUGDVEO-UHFFFAOYSA-N | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 |
2 | P35968_DB01268 | DB01268 | Sunitinib | inhibitor | Ki(nM) = 2.9 IC50(nM) = 0.4 Kd(nM) = 0.13 | WINHZLLDWRZWRT-ATVHPVEESA-N | CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C |
3 | P35968_DB04727 | DB04727 | 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea | n/a | FGZIONRFHVNRJB-UHFFFAOYSA-N | COC1=CC=C(C=C1)C1=C(C2=C(N)N=CN=C2O1)C1=CC=C(NC(=O)NC2=C(F)C=CC(=C2)C(F)(F)F)C=C1 | |
4 | P35968_DB04849 | DB04849 | Cediranib | n/a | Ki(nM) = 0.5 IC50(nM) = 0.5 Kd(nM) = 1.1 | XXJWYDDUDKYVKI-UHFFFAOYSA-N | COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1 |
5 | P35968_DB04879 | DB04879 | Vatalanib | n/a | IC50(nM) = 15.0 Kd(nM) = 62.0 | YCOYDOIWSSHVCK-UHFFFAOYSA-N | ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=CC=CC=C23)C=C1 |
6 | P35968_DB05075 | DB05075 | TG-100801 | n/a | JMGXJHWTVBGOKG-UHFFFAOYSA-N | CC1=C2N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=NC2=CC(=C1)C1=CC(OC(=O)C2=CC=CC=C2)=CC=C1Cl | |
7 | P35968_DB05984 | DB05984 | RAF-265 | n/a | YABJJWZLRMPFSI-UHFFFAOYSA-N | CN1C(NC2=CC=C(C=C2)C(F)(F)F)=NC2=CC(OC3=CC=NC(=C3)C3=NC=C(N3)C(F)(F)F)=CC=C12 | |
8 | P35968_DB06080 | DB06080 | Linifanib | n/a | MPVGZUGXCQEXTM-UHFFFAOYSA-N | CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=C3C(N)=NNC3=CC=C2)=C(F)C=C1 | |
9 | P35968_DB06436 | DB06436 | Semaxanib | n/a | WUWDLXZGHZSWQZ-WQLSENKSSA-N | CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12 | |
10 | P35968_DB06589 | DB06589 | Pazopanib | inhibitor | IC50(nM) = 30.0 Kd(nM) = 14.0 | CUIHSIWYWATEQL-UHFFFAOYSA-N | CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1 |
11 | P35968_DB06595 | DB06595 | Midostaurin | antagonist | BMGQWWVMWDBQGC-IIFHNQTCSA-N | CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1 | |
12 | P35968_DB06626 | DB06626 | Axitinib | inhibitor | RITAVMQDGBJQJZ-FMIVXFBMSA-N | CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1 | |
13 | P35968_DB06938 | DB06938 | 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide | n/a | Ki(nM) = 9.0 | ZJLSMLDOCGOURY-UHFFFAOYSA-N | CNC(=O)C1=NC=CC(OC2=CC3=C(C=C2)N=C(NC2=CC(=C(Cl)C=C2)C(F)(F)F)N3)=C1 |
14 | P35968_DB07183 | DB07183 | N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide | n/a | Ki(nM) = 10.0 IC50(nM) = 38.0 | CPVRYQAOUPSUDO-UHFFFAOYSA-N | O=C(NC1=CC=C(OC2=CC=CC=C2)C=C1)C1=C(NCC2=CC=NC=C2)N=CC=C1 |
15 | P35968_DB07274 | DB07274 | N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide | n/a | IC50(nM) = 0.6 | ZATGFXTWDKIEKC-UHFFFAOYSA-N | COC1=C(OC)C=C2C(OC3=CC4=CC=CC(C(=O)NC5CC5)=C4C=C3)=CC=NC2=C1 |
16 | P35968_DB07326 | DB07326 | 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide | n/a | IC50(nM) = 353.0 | FEGRQUWSKADGSP-UHFFFAOYSA-N | FC(F)(F)C1=CC(NC2=NOC3=C(C(=O)NC4=CN=CN=C4)C(Cl)=CC=C23)=CC=C1 |
17 | P35968_DB07333 | DB07333 | N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE | n/a | IC50(nM) = 38.0 | KRGKAARWVPUWSY-UHFFFAOYSA-N | COC1=CC=C(C=C1NC1=NC=C(O1)C1=CC(=CC=C1)C1=CN=CC=C1)S(=O)(=O)NCC1CC1 |
18 | P35968_DB07334 | DB07334 | N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE | n/a | IC50(nM) = 17.0 | HTIZPBXCJPQDEM-UHFFFAOYSA-N | CCS(=O)(=O)C1=CC=C(OC)C(NC2=NC=C(O2)C2=CC=CC(=C2)C2=CC=CC=N2)=C1 |
19 | P35968_DB07514 | DB07514 | 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one | n/a | IC50(nM) = 48.0 | LHLGUOHREUTYTO-UHFFFAOYSA-N | CC1=C(C(=O)N(C=C1)C1=CC=C2C(NCC2(C)C)=C1)C1=CC2=CN=C(N)N=C2C=C1 |
20 | P35968_DB07528 | DB07528 | 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one | n/a | IC50(nM) = 5000.0 | HXUZQEYFKAZBPX-UHFFFAOYSA-N | CC1=C(C2=CC3=C(C=C2)N=C(N)N=C3)C(=O)N(C=C1)C1=CC(=CC=C1)C(F)(F)F |
21 | P35968_DB07537 | DB07537 | N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide | n/a | IC50(nM) = 25000.0 | CLEGTVIMOPPIBR-UHFFFAOYSA-N | CC1=CC=C(C=C1C(=O)NC1=CN=C(N)C=C1)C(=O)NCCC1CCCC1 |
22 | P35968_DB08042 | DB08042 | N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine | n/a | FLXGQDHYCWXTAI-UHFFFAOYSA-N | COC1=CC(NC2=NC(=CC=N2)N(C)C2=CC3=C(C=C2)C(C)=NN3)=CC(OC)=C1OC | |
23 | P35968_DB08519 | DB08519 | N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine | n/a | IC50(nM) = 6.3 | SQQAPOSROFWHIB-UHFFFAOYSA-N | COC1=CC(NC2=NC=CC(NC3=CC=C4C(C)=NNC4=C3)=N2)=CC(OC)=C1OC |
24 | P35968_DB08875 | DB08875 | Cabozantinib | antagonist | ONIQOQHATWINJY-UHFFFAOYSA-N | COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2 | |
25 | P35968_DB08896 | DB08896 | Regorafenib | inhibitor | Ki(nM) = 4.2 IC50(nM) = 4.0 | FNHKPVJBJVTLMP-UHFFFAOYSA-N | CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1 |
26 | P35968_DB08901 | DB08901 | Ponatinib | inhibitor | Ki(nM) = 1.5 IC50(nM) = 1.5 | PHXJVRSECIGDHY-UHFFFAOYSA-N | CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1 |
27 | P35968_DB09078 | DB09078 | Lenvatinib | inhibitor | WOSKHXYHFSIKNG-UHFFFAOYSA-N | COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O | |
28 | P35968_DB09079 | DB09079 | Nintedanib | inhibitor | XZXHXSATPCNXJR-ZIADKAODSA-N | COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1 | |
29 | P35968_DB11800 | DB11800 | Tivozanib | inhibitor | SPMVMDHWKHCIDT-UHFFFAOYSA-N | COC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1 | |
30 | P35968_DB12010 | DB12010 | Fostamatinib | inhibitor | GKDRMWXFWHEQQT-UHFFFAOYSA-N | COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC | |
31 | P35968_DB12147 | DB12147 | Erdafitinib | substrate | OLAHOMJCDNXHFI-UHFFFAOYSA-N | COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1 | |
32 | P35968_DB12307 | DB12307 | Foretinib | n/a | CXQHYVUVSFXTMY-UHFFFAOYSA-N | COC1=C(OCCCN2CCOCC2)C=C2N=CC=C(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3F)C2=C1 | |
33 | P35968_DB14840 | DB14840 | Ripretinib | inhibitor | CEFJVGZHQAGLHS-UHFFFAOYSA-N | CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1 | |
34 | P35968_DB15822 | DB15822 | Pralsetinib | inhibitor | GBLBJPZSROAGMF-RWYJCYHVSA-N | CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 |